Successful tyrosine kinase inhibitor discontinuation outside clinical trials — data from the population‐based Swedish chronic myeloid leukaemia registry

Clinical trials show that tyrosine kinase inhibitor (TKI) treatment can be discontinued in selected patients with chronic myeloid leukaemia (CML). Although updated CML guidelines support such procedure clinical routine, data on TKI stopping outside are limited. In this retrospective study utilising the Swedish registry, we examined discontinuation a population-based setting. Out of 584 diagnosed chronic-phase (CML-CP) 2007–2012, 548 had evaluable information discontinuation. With median follow-up nine years from diagnosis, 128 (23%) therapy (≥1 month) due to achieving DMR (deep molecular response) and 107 (20%) other causes (adverse events, allogeneic stem cell transplant, pregnancy, etc). Among those DMR, 49% re-initiated (median time restart 4·8 months). all, 38 stopped within 90 study. After 24 months 41·1% discontinuing treatment. duration pre-stop was longer proportion treated second-generation slightly higher studies, conceivably affecting outcome. summary practice is common feasible may just as successful when performed trial.